Ultimately the Japanese provide a quicker path to market than the US. The FDA is forcing biotech to jump through too many hoops to the detriment of the US health consumer. There is a risk in new treatments but the Japanese seem willing to allow broader use of innovative treatments more quickly. With appropriate clinical monitoring, the risk can be mitigated and hopefully everybody wins with better clinical outcomes.
Lawyers and greed have had an adverse effect on the innovation that drove US pharmaceutical companies other markets and institutions will be happy to fill the void as Japan is obviously doing.
Ultimately the Japanese provide a quicker path to market than...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.030(1.90%) |
Mkt cap ! $1.832B | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.65 | $1.59 | $7.014M | 4.343M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 342 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 54534 | 8 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |